Table 3.

Adverse events

	Overall (N = 88)			Standard (N = 40)			Bi-weekly (N = 42)
	Any grade	Grade 3	Grade 4	Any grade	Grade 3	Grade 4	Any grade	Grade 3	Grade 4
Hematologic events, n (%)
Leukopenia	73 (83.0)	32 (36.4)	8 (9.1)	29 (72.5)	9 (22.5)	2 (5.0)	40 (95.2)	22 (52.4)	3 (7.1)
Neutropenia	68 (77.3)	28 (31.8)	24 (27.3)	25 (62.5)	9 (22.5)	3 (7.5)	39 (92.9)	18 (42.9)	19 (45.2)
Anemia	51 (58.0)	3 (3.4)	0	24 (60.0)	3 (7.5)	0	23 (54.8)	0	0
Thrombocytopenia	16 (18.2)	3 (3.4)	0	9 (22.5)	2 (5.0)	0	5 (11.9)	0	0
Febrile neutropenia	7 (8.0)	7 (7.0)	0	1 (2.5)	1 (2.5)	0	5 (11.9)	5 (11.9)	0
Non-hematologic events, n (%)
AST increased	45 (51.1)	3 (3.4)	0	18 (45.0)	0	0	24 (57.1)	2 (4.8)	0
Alopecia	50 (56.8)	0	0	26 (65.0)	0	0	23 (54.8)	0	0
Peripheral sensory neuropathy	42 (47.7)	1 (1.1)	0	18 (45.0)	0	0	22 (52.4)	1 (2.4)	0
Fatigue	50 (56.8)	5 (5.7)	0	24 (60.0)	4 (10.0)	0	22 (52.4)	1 (2.4)	0
Malaise	46 (52.3)	0	0	22 (55.0)	0	0	19 (45.2)	0	0
ALT increased	37 (42.0)	2 (2.3)	0	17 (42.5)	0	0	18 (42.9)	2 (4.8)	0
Nausea	32 (36.4)	1 (1.1)	0	15 (37.5)	0	0	17 (40.5)	1 (2.4)	0
Dysgeusia	32 (36.4)	0	0	18 (45.0)	0	0	12 (28.6)	0	0
Mucositis oral	21 (23.9)	1 (1.1)	0	9 (22.5)	0	0	11 (26.2)	1 (2.4)	0
Pain	24 (27.3)	3 (3.4)	0	12 (30.0)	0	0	9 (21.4)	2 (4.8)	0
Constipation	18 (20.5)	0	0	8 (20.0)	0	0	8 (19.0)	0	0
Peripheral motor neuropathy	14 (15.9)	2 (2.3)	0	4 (10.0)	0	0	8 (19.0)	1 (2.4)	0
Nail discoloration	11 (12.5)	0	0	5 (12.5)	0	0	6 (14.3)	0	0
Edema limbs	9 (10.2)	0	0	4 (10.0)	0	0	5 (11.9)	0	0
Rash maculo-papular	4 (4.5)	1 (1.1)	0	0	0	0	4 (9.5)	1 (2.4)	0
Vomiting	5 (5.7)	0	0	2 (5.0)	0	0	3 (7.1)	0	0
Pharyngitis	4 (4.5)	0	0	1 (2.5)	0	0	3 (7.1)	0	0
Diarrhea	5 (5.7)	0	0	3 (7.5)	0	0	2 (4.8)	0	0
Blood bilirubin increased	7 (8.0)	0	0	3 (7.5)	0	0	2 (4.8)	0	0
Nail loss	1 (1.1)	0	0	0	0	0	1 (2.4)	0	0
Skin hyperpigmentation	3 (3.4)	0	0	2 (5.0)	0	0	1 (2.4)	0	0
Creatinine increased	9 (10.2)	2 (2.3)	0	7 (17.5)	2 (5.0)	0	1 (2.4)	0	0

ALT alanine aminotransferase, AST aspartate aminotransferase